t
| Date | 15 Mar 2023 |
| Time | 07:00:10 |
| Category | Results |
| ID | 9774S |
Sareum Holdings PLC
("Sareum" or the "Company")
Notice of Half-Year Results and Investor Presentation
Cambridge, UK, 15 March 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, will announce its unaudited results for the six months ended 31 December 2022 on Wednesday, 22 March 2023.
The Company will be holding a presentation to investors on Wednesday, 22 March 2023 at 12.30 pm GMT via the Investor Meet Company ("IMC") platform.
Investors can sign up to Investor Meet Company for free and add to meet SAREUM HOLDINGS PLC via: https://www.investormeetcompany.com/sareum-holdings-plc/register-investor
Investors who already follow SAREUM HOLDINGS PLC on the Investor Meet Company platform will automatically be invited.
A copy of the presentation will be made available on the Company's website following the presentation.
- Ends -
For further information, please contact:
|
Sareum Holdings plc Tim Mitchell, CEO Alexandra Harrison, Head of IR
|
01223 497700
|
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Peel Hunt LLP (Joint Corporate Broker) James Steel / Oliver Duckworth
|
020 7418 8900 |
|
Hybridan LLP (Joint Corporate Broker) Claire Noyce
|
020 3764 2341 |
|
Consilium Strategic Communications (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki |
0203 709 5700 |
About Sareum
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, which, is planned to enter clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com